Honeycomb Therapeutics is operating at the nexus between cell therapy, synthetic biology and biologics. We aim to revolutionize how biologics are administered. Rather than using cells as the therapeutic, we will engineer a long-lived cell type called B cells to make and deliver the therapeutics within the patient’s own body. Using advanced cell engineering technologies, we will engineer autonomous B cells capable of controlling the precise dose and timing of therapeutic release. Our goal is to create cell therapies that effectively treat disease while avoiding unwanted side effects associated with systemic delivery systems. We aim to use pluripotent stem cells as a scalable, low cost source of quality-controlled B cell therapy products. Our vision is to provide a safe, effective and accessible cell therapy solution for a broad range of complex indications.